AI and digital transformation in cell and gene therapy: enabling scalable and predictable biomanufacturing
Cell and Gene Therapy Insights · 06.08.2026 · 12 (6) · 697–709
DOI: 10.18609/cgti.2026.084 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell and Gene Therapy Insights, online erschienen am 06.08.2026. Verfasst von Preeti Misra. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Cell and gene therapy (CGT) has demonstrated transformative clinical potential; however, challenges in scalability, cost, and process consistency continue to limit widespread adoption. AI and digital transformation are emerging as critical enablers to address these bottlenecks. From predictive vector design to smart manufacturing and real-time quality control, AI-driven approaches are reshaping the CGT lifecycle. This article explores how integrated digital ecosystems, advanced analytics, and automation accelerate CGT industrialization while highlighting key implementation challenges and regulatory considerations.
Zitieren
APA
Misra, P. (2026). AI and digital transformation in cell and gene therapy: enabling scalable and predictable biomanufacturing. Cell and Gene Therapy Insights, 12(6), 697–709. https://doi.org/10.18609/cgti.2026.084
Vancouver
Misra P. AI and digital transformation in cell and gene therapy: enabling scalable and predictable biomanufacturing. Cell and Gene Therapy Insights. 2026;12(6):697–709. doi:10.18609/cgti.2026.084
BibTeX
@article{Misra2026,
author = {Misra, Preeti},
title = {AI and digital transformation in cell and gene therapy: enabling scalable and predictable biomanufacturing},
journal = {Cell and Gene Therapy Insights},
year = {2026},
volume = {12},
number = {6},
pages = {697–709},
doi = {10.18609/cgti.2026.084}
}
EUVIMED